Revolutionizing cancer care with a robust pipeline, cutting-edge therapies, and 20 near-term milestones
Global oncology leader BeOne Medicines Ltd., Based in USA (NASDAQ: ONC; HKEX: 06160; SSE: 688235) has taken center stage with its highly anticipated R&D Day, where the company showcased pivotal data from its expansive pipeline. With over 40 clinical and commercial-stage assets and a clear commitment to accelerating cancer research and access, the event marks a defining moment in BeOne’s mission to shape the future of oncology.
At the heart of BeOne’s success is a focused ambition—to build the world’s leading next-generation oncology company. “Our goal is not only to treat cancer but to transform the way cancer is treated,” said John V. Oyler, Co-Founder, Chairman, and CEO of BeOne. “The science we shared today shows the extraordinary progress our team has made—and highlights the promise that lies ahead.”
Leading in Hematology: BRUKINSA, Sonrotoclax & BTK CDAC
BeOne’s hematologic cancer portfolio features powerful assets like BRUKINSA® (zanubrutinib), a next-gen BTK inhibitor, and sonrotoclax, a potential best-in-class BCL2 inhibitor. Together, they form the backbone of a pipeline targeting chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
One of the highlights of the day was new clinical data from BGB-16673, a BTK CDAC and first-in-class BTK degrader. Early results from the CaDAnCe-101 trial show encouraging potential for relapsed or refractory CLL patients. BeOne also presented compelling findings on the combination of BRUKINSA and sonrotoclax, positioning it as a fixed-duration treatment that could redefine the standard of care for CLL.
Solid Tumor Strategy: Innovations in Breast, Lung, and GI Cancers
In solid tumors, BeOne has expanded beyond its foundational PD-1 inhibitor TEVIMBRA® (tislelizumab-jsgr) with a suite of next-generation therapies. The company announced that its CDK4 inhibitor (BGB-43395) has demonstrated strong pharmacodynamic activity and is set to enter registration-enabling studies for breast cancer in the next six to 12 months.
Another promising candidate is the B7-H4 antibody-drug conjugate (BG-C9074), which is showing first-in-class potential in treating tumors with high B7-H4 expression, including those without biomarker selection criteria. Additionally, an early-stage PRMT5 inhibitor has demonstrated a strong safety profile and promising efficacy in lung cancer, setting the foundation for a new therapeutic option in a competitive space.
A Scalable, Integrated Model Driving Rapid Innovation
What sets BeOne apart is its integrated, global model. The company boasts over 11,000 employees, including 1,200 scientists and 3,700 clinical and medical affairs experts working across six continents. BeOne has already conducted 170+ clinical trials across 40 countries, involving more than 25,000 patients. Its in-house manufacturing hubs, including a flagship facility in Hopewell, NJ, allow for rapid development and scalable global operations.
“Our R&D infrastructure is built for both speed and excellence,” said Dr. Lai Wang, Global Head of R&D. “We’ve created an agile, high-output engine that turns novel ideas into real-world impact—fast. Over the next 18 months, we expect 20 near-term clinical milestones. That kind of momentum is rare in this industry.”
Global Vision, Local Impact
Now headquartered in Switzerland, BeOne Medicines is driving its global vision with strong regional execution. Its redomiciling earlier this year signals a renewed focus on global collaboration, access, and affordability.
Today’s event featured presentations from BeOne’s executive team, senior R&D leaders, and external key opinion leaders, highlighting the company’s deep scientific bench and global ambition. The live webcast is available via the BeOne investor portal and will be archived for on-demand viewing.
As BeOne continues to grow its presence in the global oncology landscape, the 2025 R&D Day firmly establishes the company as a formidable innovator—one that’s not just aiming to participate in the fight against cancer, but to lead it.
